Genitourinary Cancers Following Kidney Transplant: Our 20 Years of Experience With Mechanistic Target of Rapamycin Inhibitors

Basit Öğe Kaydı
dc.authoridOkut, Gokalp/0000-0002-3641-5625
dc.contributor.authorKaratas, Murat
dc.contributor.authorOkut, Gokalp
dc.contributor.authorSimsek, Cenk
dc.contributor.authorDogan, Sait Murat
dc.contributor.authorZengel, Baha
dc.contributor.authorAlkan, Funda Tasli
dc.contributor.authorTatar, Erhan
dc.date.accessioned2024-08-04T20:51:51Z
dc.date.available2024-08-04T20:51:51Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description17th Virtual Congress of the Middle-East-Society-for-Organ-Transplantation (MESOT) -- SEP 03-05, 2021 -- ELECTR NETWORKen_US
dc.description.abstractObjectives:We investigated patientswithgenitourinary cancer after kidney transplant and the effects of immunosuppression reduction and switching to mechanistic target of rapamycin inhibitors. Materials and Methods: We retrospectively evaluated kidney transplant recipients seen at our center between January 2000 and January 2020. Patients with <1 year of follow-up were excluded. Results: Of 827 patients, genitourinary cancer was detected in 11 (1.3%): prostate cancer in 5 patients (45%), renal cell carcinoma in native kidney in 3 (27%), renal cell carcinoma in allograft kidney in 2 (18%), and transitional cell carcinoma of the bladder in 1 (9%). All patients had surgery. Two patients had bone metastasis due to prostate cancer at diagnosis. Two patients had allograft nephrectomy due to de novo renal cell carcinoma. Mean followup and age were 97 +/- 45 months (range, 26-189) and 50 +/- 10.2 years (19% female). After cancer diagnosis, excluding the 2 patients with allograft nephrectomy, immunosuppression was changed in 8 patients (88.8%) (1 patient received the same treatment before and after cancer diagnosis). Six patients received double-drug and 3 received triple-drug protocols. Of 9 patients, 2 were already using mechanistic target of rapamycin inhibitors before cancer diagnosis and 7 were switched: 4 to double-based and 3 to triplebased regimens. Six were switched from tacrolimus. With new treatments, patients showed no progressive kidney failure or rejection (38 +/- 40 mo average follow-up). At last follow-up, mean glomerular filtration rate was 62.8 +/- 34 mL/min/1.72 m2, which was similar to rate at cancer diagnosis (58.9 +/- 24 mL/ min/1.72 m2; P =.78). During follow-up, no patients developed local recurrence of primary tumor or new metastasis, and none showed adverse effects after switch to mechanistic target of rapamycin inhibitors. Three patients died of malignancy-unrelated reasons (ileus, urinary sepsis, heart failure). Conclusions: Mechanistictarget of rapamycin inhibitorbased drugs can be an important maintenance immunosuppressive treatment option for kidney transplant recipients with genitourinary cancers.en_US
dc.description.sponsorshipMiddle E Soc Organ Transplantaten_US
dc.identifier.doi10.6002/ect.MESOT2021.P72
dc.identifier.endpage148en_US
dc.identifier.issn1304-0855
dc.identifier.issn2146-8427
dc.identifier.issue3en_US
dc.identifier.pmid35384826en_US
dc.identifier.scopus2-s2.0-85127710863en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://doi.org/10.6002/ect.MESOT2021.P72
dc.identifier.urihttps://hdl.handle.net/11616/100592
dc.identifier.volume20en_US
dc.identifier.wosWOS:000915505100029en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBaskent Univen_US
dc.relation.ispartofExperimental and Clinical Transplantationen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectClinical outcomesen_US
dc.subjectDe novo malignancyen_US
dc.subjectGraft survivalen_US
dc.subjectmTORien_US
dc.titleGenitourinary Cancers Following Kidney Transplant: Our 20 Years of Experience With Mechanistic Target of Rapamycin Inhibitorsen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu